Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.67 |
| ▸ | NOS1 | P29475 | 1/20 | 0.67 |
| ▸ | NOS2 | P35228 | 1/20 | 0.67 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.50 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218547 | 0.86 | NOS3 (0.52) | NOS3NOS1NOS2CHRNB4CHRNA3 | |
| SCHEMBL3435522 | 0.82 | NOS3 (0.47) | NOS3NOS1NOS2CHRNB4CHRNA3 | |
| SCHEMBL5833762 | 0.81 | NOS3 (1.00) | NOS3NOS1NOS2CHRNB4CHRNA3 | |
| SCHEMBL13849433 | 0.79 | CHRNB4 (0.66) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL221914 | 0.79 | NOS3 (0.63) | NOS3NOS1NOS2 | |
| SCHEMBL221387 | 0.78 | NOS1 (0.46) | NOS3NOS1NOS2 | |
| SCHEMBL5833036 | 0.78 | NOS3 (0.94) | NOS3NOS1NOS2CHRNB4CHRNA3 | |
| SCHEMBL13849434 | 0.77 | CHRNB4 (0.66) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL221859 | 0.76 | NOS1 (0.57) | NOS3NOS1NOS2CHEK1 | |
| SCHEMBL13849332 | 0.76 | CHRNB4 (0.67) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| JP-2003523941-A | — | — | 2003-08-12 | — | — | JP | claimed |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-0958282-B1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | PFIZER PROD INC (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | PFIZER INC. | 2001-07-12 | — | — | US | disclosed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | NOS3 157/4885NOS1 110/4885NOS2 192/4885 |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | NOS1, PTGS1, NOS2 | NOS3 4/4885NOS1 1/4885NOS2 3/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | NOS3 2/4885NOS1 1/4885NOS2 6/4885 |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | GRIN2C, GRIN2A, CNR2 | NOS3 2496/4885NOS1 2484/4885NOS2 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.